A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza (Formerly Known as Omacor) Therapy in Hypertriglyceridemic Subjects Treated With Antara.

Trial Profile

A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza (Formerly Known as Omacor) Therapy in Hypertriglyceridemic Subjects Treated With Antara.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jan 2011

At a glance

  • Drugs Fenofibrate; Omega-3-acid ethyl esters
  • Indications Hypertriglyceridaemia
  • Focus Biomarker; Therapeutic Use
  • Sponsors GlaxoSmithKline; Reliant Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jun 2009 Planned end date changed from 1 Feb 2007 to 1 Mar 2007 as reported by ClinicalTrials.gov.(NCT00246636).
    • 09 Jun 2009 Planned end date changed from 1 Feb 2007 to 1 Mar 2007 as reported by ClinicalTrials.gov.(NCT00246636).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top